Sugi Predict

Sugi Predict / Compounds / SCHEMBL2837656

SCHEMBL2837656

SCHEMBL2837656

O=S(=O)(Cl)c1cccc(Oc2ccccc2)c1

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.56
▸ HSD17B10 Q99714 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ PGR P06401 9/20 0.49
▸ SOS1 Q07889 1/20 0.48
▸ CTSG P08311 1/20 0.48
▸ CMA1 P23946 1/20 0.48
▸ KAT6A Q92794 1/20 0.48
▸ AKR1C3 P42330 1/20 0.47
▸ MAOB P27338 1/20 0.47
▸ LTA4H P09960 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ PPARG P37231 1/20 0.45
▸ HTT P42858 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4833629 0.87 PGR (0.49) TDP1PGRSOS1MAOBPPARG
SCHEMBL14572646 0.86 HTT (0.62) ALDH1A1TDP1PGRSOS1HTT
SCHEMBL14257046 0.86 SOS1 (0.50) TDP1PGRSOS1HTT
SCHEMBL14572638 0.86 PGR (0.58) ALDH1A1TDP1PGRLTA4HHTT
SCHEMBL9779108 0.84 HTT (0.56) TDP1PGRSOS1CTSGCMA1
SCHEMBL14572635 0.84 TERT (0.46) ALDH1A1HSD17B10TDP1PGRHTT
SCHEMBL1304736 0.82 HTT (0.53) ALDH1A1HSD17B10TDP1PGRSOS1
SCHEMBL14572495 0.82 KMO (0.54) PGRSOS1
SCHEMBL3923038 0.82 PGR (0.51) TDP1PGRHTT
SCHEMBL31244 0.82 SOS1 (0.64) ALDH1A1HSD17B10TDP1PGRSOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595243-B2 Modulators of extracellular signal-regulated kinase GEN1E LIFESCIENCES INC. (US) 2026-04-07 — — US disclosed
US-20250136571-A1 MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE GEN1E LIFESCIENCES INC. 2025-05-01 — — US disclosed
WO-2025085745-A1 MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE GEN1E LIFESCIENCES INC. (US) 2025-04-24 — — WO disclosed
US-20240124428-A1 HETEROCYCLIC INHIBITORS OF PCSK9 Cardio Therapeutics Pty Ltd (AU) 2024-04-18 — — US disclosed
EP-4263520-A1 HETEROCYCLIC INHIBITORS OF PCSK9 Cardio Therapeutics Pty Ltd (AU) 2023-10-25 — — EP disclosed
WO-2022133529-A1 HETEROCYCLIC INHIBITORS OF PCSK9 Cardio Therapeutics Pty Ltd (AU) 2022-06-30 — — WO disclosed
WO-2022133529-A1 HETEROCYCLIC INHIBITORS OF PCSK9 Cardio Therapeutics Pty Ltd (AU) 2022-06-30 — — WO disclosed
WO-2021123237-A1 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE Oxford Drug Design Limited (GB) 2021-06-24 — — WO disclosed
EP-1648867-B1 PPAR ACTIVE COMPOUNDS PLEXXIKON INC (US) 2013-09-04 — — EP disclosed
US-8410150-B2 Inhibitors of carnitine palmitoyltransferase and treating cancer UNIVERSITY HEALTH NETWORK (CA) 2013-04-02 — — US disclosed
EP-1648867-A1 PPAR ACTIVE COMPOUNDS PLEXXIKON, INC. (US) 2006-04-26 — — EP disclosed
US-20050288354-A1 PPAR active compounds PLEXXIKON, INC. 2005-12-29 — — US disclosed
US-20050038246-A1 PPAR active compounds PLEXXIKON, INC. 2005-02-17 — — US disclosed
WO-2005009958-A1 PPAR ACTIVE COMPOUNDS PLEXXIKON, INC. (US) 2005-02-03 — — WO disclosed
EP-1086076-B1 SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMA (US) 2004-12-22 — — EP disclosed
US-20040097594-A1 Sulfonamide inhibitors of aspartyl protease HALE MICHAEL ROBIN (US) 2004-05-20 — — US disclosed
US-6613743-B2 Administering to a patient suffering from viral infections a sulfonamides antiviral agents which are aspartyl protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2003-09-02 — — US disclosed
US-20020049201-A1 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED 2002-04-25 — — US disclosed
EP-1086076-A1 SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE Vertex Pharmaceuticals Incorporated (US) 2001-03-28 — — EP disclosed
WO-1999065870-A2 SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 1999-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097594-A1 Sulfonamide inhibitors of aspartyl protease SPINT2, PRSS1, DNPEP ALDH1A1 1841/4885HSD17B10 1425/4885TDP1 798/4885
US-20050038246-A1 PPAR active compounds PPARG, PPARD, PPARA ALDH1A1 1171/4885HSD17B10 290/4885TDP1 3738/4885
US-20020049201-A1 Sulfonamide inhibitors of aspartyl protease SPINT2, PRSS1, DNPEP ALDH1A1 1841/4885HSD17B10 1425/4885TDP1 798/4885
US-20240124428-A1 HETEROCYCLIC INHIBITORS OF PCSK9 PCSK9, PCSK7, PCSK6 ALDH1A1 3487/4885HSD17B10 260/4885TDP1 875/4885
US-20250136571-A1 MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE MAP3K20, MAP3K6, CDC42BPG ALDH1A1 4211/4885HSD17B10 4563/4885TDP1 3395/4885
US-20050288354-A1 PPAR active compounds PPARG, PPARD, PPARA ALDH1A1 1171/4885HSD17B10 290/4885TDP1 3738/4885
US-12595243-B2 Modulators of extracellular signal-regulated kinase CDC42BPG, GRK3, ERBB2 ALDH1A1 2876/4885HSD17B10 2235/4885TDP1 3752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.